The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder

References

• Akula N, Barb J, Jiang X, Wendland JR, Choi KH, Sen SK, Hou L, Chen DTW, Laje G, Johnson K, et al. 2014. RNA-sequencing of the brain transcriptome implicates dysregulation of neuroplasticity, circadian rhythms and GTPase binding in bipolar disorder. Mol Psychiatry. 19:1179–1185.
   PubMed Web of Science ®Google Scholar
• Aston C, Jiang L, Sokolov BP. 2005. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry. 10:309–322.
   PubMed Web of Science ®Google Scholar
• Bahi A, Schwed JS, Walter M, Stark H, Sadek B. 2014. Anxiolytic and antidepressant-like activities of the novel and potent non-imidazole histamine Hâ receptor antagonist ST-1283. Drug Des Devel Ther. 8:627–637.
   PubMed Web of Science ®Google Scholar
• Bai Y-M, Su T-P, Tsai S-J, Wen-Fei C, Li C-T, Pei-Chi T, Mu-Hong C. 2014. Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. J Affect Disord. 166:187–192.
   PubMed Web of Science ®Google Scholar
• Becker D, Grinberg Y, Weizman A, Mester R. 2002. Association between flupenthixol treatment and emergence of manic symptoms. Eur Psychiatry. 17:349–352.
   PubMed Web of Science ®Google Scholar
• Belvederi Murri M, Prestia D, Mondelli V, Pariante C, Patti S, Olivieri B, Arzani C, Masotti M, Respino M, Antonioli M, et al. 2016. The HPA axis in bipolar disorder: Systematic review and meta-analysis. Psychoneuroendocrinology 63:327–342.
   PubMed Web of Science ®Google Scholar
• Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS, Dodd S, Dean B, et al. 2011. Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 35:804–817.
   PubMed Web of Science ®Google Scholar
• Daban C, Vieta E, Mackin P, Young AH. 2005. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am. 28:469–480.
   PubMed Web of Science ®Google Scholar
• de Souza Gomes JA, de Souza GC, Berk M, Cavalcante LM, de Sousa FCF, Budni J, de Lucena DF, Quevedo J, Carvalho AF, Macêdo D, et al. 2015. Antimanic-like activity of candesartan in mice: Possible involvement of antioxidant, anti-inflammatory and neurotrophic mechanisms. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology. 25:2086–2097.
   PubMed Web of Science ®Google Scholar
• Diaz-Trelles R, Fernandez-Sanchez MT, Marini AM, Novelli A. 2002. Antihistamine terfenadine inhibits calcium influx, cGMP formation, and NMDA receptor-dependent neurotoxicity following activation of L-type voltage sensitive calcium channels. Neurotox Res. 4:15–24.
   PubMed Web of Science ®Google Scholar
• Djurovic S, Gustafsson O, Mattingsdal M, Athanasiu L, Bjella T, Tesli M, Agartz I, Lorentzen S, Melle I, Morken G, et al. 2010. A genome-wide association study of bipolar disorder in Norwegian individuals, followed by replication in Icelandic sample. J Affect Disord. 126:312–316.
   PubMed Web of Science ®Google Scholar
• Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD. 2008. The histamine H3 receptor: An attractive target for the treatment of cognitive disorders. Br J Pharmacol. 154:1166–1181.
   PubMed Web of Science ®Google Scholar
• Golden JC, Goethe JW, Woolley SB. 2017. Complex psychotropic polypharmacy in bipolar disorder across varying mood polarities: A prospective cohort study of 2712 inpatients. J Affect Disord. 221:6–10.
   PubMed Web of Science ®Google Scholar
• Grover MP, Ballouz S, Mohanasundaram KA, George RA, Sherman CDH, Crowley TM, Wouters MA. 2014. Identification of novel therapeutics for complex diseases from genome-wide association data. BMC Med Genomics. 7(Suppl 1):S8.
   PubMed Web of Science ®Google Scholar
• Hyman SE. 2013. Psychiatric drug development: Diagnosing a crisis. Cerebrum. 2013:5.
   PubMedGoogle Scholar
• Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. 2013. TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions [journal article]. Genome Biol. 14:R36.
   PubMed Web of Science ®Google Scholar
• Kishi T, Oya K, Iwata N. 2016. Long-acting injectable antipsychotics for prevention of relapse in bipolar disorder: A systematic review and meta-analyses of randomized controlled trials. Neuropsychopharmacology. 19:pyw038.
   Web of Science ®Google Scholar
• Köhler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, Krogh J. 2014. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 71:1381–1391.
   PubMed Web of Science ®Google Scholar
• Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet J-P, Subramanian A, Ross KN, et al. 2006. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 313:1929–1935.
   PubMed Web of Science ®Google Scholar
• Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, Kupfer DJ. 2012. Can bipolar disorder be viewed as a multi-system inflammatory disease? Journal of Affective Disorders. 141:1–10.
   PubMed Web of Science ®Google Scholar
• Magno LAV, Santana CVN, Sacramento EK, Rezende VB, Cardoso MV, Maurício-da-Silva L, Neves FS, Miranda DM, De Marco LA, Correa H, et al. 2011. Genetic variations in FOXO3A are associated with bipolar disorder without confering vulnerability for suicidal behavior. J Affect Disord. 133:633–637.
   PubMed Web of Science ®Google Scholar
• Maletic V, Raison C. 2014. Integrated neurobiology of bipolar disorder. Front Psychiatry. 5:98.
   PubMed Web of Science ®Google Scholar
• Medina A, Burke S, Thompson RC, Bunney W, Myers RM, Schatzberg A, Akil H, Watson SJ. 2013. Glutamate transporters: a key piece in the glutamate puzzle of major depressive disorder. Journal of Psychiatric Research. 47:1150–1156.
   PubMed Web of Science ®Google Scholar
• Mojtabai R, Olfson M. 2010. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry. 67:26–36.
   PubMed Web of Science ®Google Scholar
• Pleasure SJ, Page C, Lee VM. 1992. Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons. J Neurosci. 12:1802–1815.
   PubMed Web of Science ®Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. 2010. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 26:139–140.
   PubMed Web of Science ®Google Scholar
• Rosenblat JD, Kakar R, Berk M, Kessing LV, Vinberg M, Baune BT, Mansur RB, Brietzke E, Goldstein BI, McIntyre RS, et al. 2016. Anti-inflammatory agents in the treatment of bipolar depression: A systematic review and meta-analysis. Bipolar Disord. 18:89–101.
   PubMed Web of Science ®Google Scholar
• Sachs GS, Peters AT, Sylvia L, Grunze H. 2014. Polypharmacy and bipolar disorder: What's personality got to do with it? Int J Neuropsychopharmacol. 17:1053–1061.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Treccani G, Popoli M. 2012. Towards a glutamate hypothesis of depression: An emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 62:63–77.
   PubMed Web of Science ®Google Scholar
• Scarr E, Udawela M, Dean B. 2018. Changed frontal pole gene expression suggest altered interplay between neurotransmitter, developmental, and inflammatory pathways in schizophrenia. Npj Schizophr. 4:4.
   PubMed Web of Science ®Google Scholar
• Sklar P, Smoller JW, Fan J, Ferreira MAR, Perlis RH, Chambert K, Nimgaonkar VL, McQueen MB, Faraone SV, Kirby A, et al. 2008. Whole-genome association study of bipolar disorder. Mol Psychiatry. 13:558–569.
   PubMed Web of Science ®Google Scholar
• Stuart MJ, Baune BT. 2014. Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: A systematic review of biomarker studies. Neurosci Biobehav Rev. 42:93–115.
   PubMed Web of Science ®Google Scholar
• Vizlin-Hodzic D, Zhai Q, Illes S, Södersten K, Truvé K, Parris TZ, Sobhan PK, Salmela S, Kosalai ST, Kanduri C, et al. 2017. Early onset of inflammation during ontogeny of bipolar disorder: The NLRP2 inflammasome gene distinctly differentiates between patients and healthy controls in the transition between iPS cell and neural stem cell stages. Transl Psychiatry. 7:e1010.
   PubMed Web of Science ®Google Scholar
• Williams LJ, Pasco JA, Kessing LV, Quirk SE, Fernandes BS, Berk M. 2016. Angiotensin converting enzyme inhibitors and risk of mood disorders. Psychother Psychosom. 85:250–252.
   PubMed Web of Science ®Google Scholar
• Wimalasena NK, Le VQ, Wimalasena K, Schreiber SL, Karmacharya R. 2016. Gene expression-based screen for Parkinson's disease identifies GW8510 as a neuroprotective agent. ACS Chem Neurosci. 7:857–863.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, Macqueen G, McIntyre RS, Sharma V, et al. 2013. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 15:1–44.
   PubMed Web of Science ®Google Scholar
• Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Nicol Ferrier I. 2004. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology. 29:1538–1545.
   PubMed Web of Science ®Google Scholar
• Young JP, Hughes WC, Lader MH. 1976. A controlled comparison of flupenthixol and amitriptyline in depressed outpatients. Br Med J. 1:1116–1118.
   PubMed Web of Science ®Google Scholar